2024-09-28T12:00:00
KELIM presented at the international PSOGI ISSP1 ESGO congress
The first consensual meeting about Peritoneal surface malignancies involving PSOGI, ISSP and ESGO was organized in Lyon, France from 26 to 28th September 2024. A big success for KELIM across several countries on the globe !
2024-08-23T12:00:00
SALVOVAR phase III trial: Activated in France and Japan => Already 5 patients enrolled !
SALVOVAR is a phase III trial meant to show that densification of the chemotherapy with the weekly dose-dense paclitaxel in patients presenting with an unfavorable KELIM score < 1.0 and a disease not amenable to complete interval debulking surgery could improve their prognosis. For more details : https://salvovar-cms-uploads.s3.fr-par.scw.cloud/e2898237-e03b-4554-85e8-a2440af3e56d.mp4
2023-10-20T12:00:00
Meeting for SALVOVAR project at ESMO 2023
The partners, investigators and investigating groups of SALVOVAR project are invited to join for a face to face meeting at Madrid on October 20th 2023 at 12:00 am for partners and 2 pm for investigators Site: Novotel Madrid Campo de las Naciones (Hotel Novotel Madrid Campo de las Naciones) - Campo De Las Naciones, C. de Ámsterdam, N° 3, 28042 Madrid, Spain Just facing the convention center
2023-09-29T12:00:00
KELIM presented at ESGO 2023 !
Biomarker-Kinetics and KELIM were presented at ESGO 2023 in a session entitled "PARPi for the better or the worse ?"
2023-07-04T12:00:00
KELIM™ prognostic value in the GCIG meta-analysis dataset accepted in EJC
We are pleased to announce that the article about KELIM™ prognostic value in the GCIG meta-analysis dataset written by Pauline Corbaux was accepted for publication in the European Journal of Cancer !